A Phase II Randomized Study of Induction Therapy Comparing Cytarabine, Daunorubicin, and Quizartinib vs Azacitidine, Venetoclax, and Quizartinib in FLT3-ITD Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy

This phase II MyeloMATCH treatment trial compares the combination of azacitidine, venetoclax and quizartinib to the standard treatment of cytarabine, daunorubicin and quizartinib for the treatment of patients with FLT3-ITD mutant acute myeloid leukemia. Azacitidine and quizartinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as cytarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving azacitidine, venetoclax and quizartinib may be more effective than giving cytarabine, daunorubicin and quizartinib for the treatment of patients with FLT3-ITD mutant acute myeloid leukemia.

开始日期2027-01-15

申办/合作机构

National Cancer Institute

NCT06954987

/ Not yet recruiting临床2期IIT

A Two Cohort, Randomized, Double-Blind, Placebo-Controlled, Phase II Multi-Center Signal-Finding Study of Venetoclax Combined With Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Cell Transplantation Then Venetoclax Maintenance in Adult Patients With Acute Myeloid Leukemia in First Complete Remission: A MyeloMATCH Sub-Study

This phase II MyeloMATCH treatment trial compares the effect of adding venetoclax or placebo to reduced intensity conditioning chemotherapy with fludarabine and busulfan or melphalan, with or without total body irradiation, followed by hematopoietic stem cell transplant and either venetoclax or placebo maintenance therapy after transplant, for the treatment of patients with acute myeloid leukemia (AML). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving chemotherapy and total body irradiation before a donor stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When the healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets and may help destroy any remaining cancer cells. Adding venetoclax to conditioning therapy before, and giving it as maintenance therapy after, a hematopoietic stem cell transplant may be a more effective treatment option than the usual approach in patients with AML.

开始日期2027-01-15

申办/合作机构

National Cancer Institute

100 项与维奈克拉相关的临床结果

登录后查看更多信息

100 项与维奈克拉相关的转化医学

登录后查看更多信息

100 项与维奈克拉相关的专利（医药）

登录后查看更多信息

5,515

项与维奈克拉相关的文献（医药）

2027-02-01·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Integrative Systems Biology Prioritizes BCL2, ALK, and CDK4 as Therapeutic Candidates in Neuroblastoma through Multi‐Centrality Network Analysis, Cross‐Database Validation, Independent Docking Validation, and Confidence‐Threshold Sensitivity Analysis

Article

作者: Zabihi, Abbas

BACKGROUND:

Neuroblastoma remains a therapeutic challenge due to its molecular heterogeneity, yet the convergent network topology of its oncogenic interactome has not been systematically characterized using multi-criteria computational approaches. An integrative computational framework combining network-based hub gene prioritization, cross-database biological validation, and structure-based drug-target assessment is needed to identify and prioritize therapeutic molecular targets.

METHODS:

An integrative computational pipeline was developed comprising (i) batch-effect correction (ComBat) and differential expression analysis of two neuroblastoma microarray datasets (GSE10927, GSE16476); (ii) protein-protein interaction (PPI) network reconstruction (STRING v11.5) and multi-criteria candidate identification using six complementary centrality metrics (degree, betweenness, closeness, MCC, MNC, EPC); (iii) modular decomposition (Louvain algorithm) and functional enrichment analysis (GO, KEGG, WikiPathways); (iv) miRNA regulatory network analysis (DIANA-miRPath/TarBase); (v) independent cross-validation against six external databases (TARGET-NBL, Human Protein Atlas, CCLE, DepMap, GDSC, cBioPortal); (vi) molecular docking (HDOCK) and 100-ns molecular dynamics simulations (one trajectory per complex) with trajectory analysis (RMSD, RMSF, Rg, hydrogen-bond occupancy); and (vii) two revision-stage verification analyses: an independent AutoDock Vina re-docking validation of the five drug-target pairs and their co-crystallized ligands, and a confidence-threshold sensitivity analysis of the PPI network (0.400/0.700/0.900) computed on the version-locked STRING v11.5 release restricted to the exported hub node set.

RESULTS:

The batch-corrected transcriptomic integration effectively separated tumors from normal samples (PCA, 82.9% variance explained). Multi-criteria network analysis prioritized BCL2, ALK, MYCN, CDK4, and MAPT as leading candidates. Modular decomposition revealed seven functional clusters spanning cell cycle regulation, apoptosis, MAPK signaling, and neuronal differentiation. BCL2, ALK, and CDK4 showed multi-database validation concordance: transcriptomic overexpression (TARGET-NBL, log2FC = 1.84 for BCL2, FDR < 0.001), protein-level confirmation (Human Protein Atlas), selective gene dependency (DepMap CRISPR), and pharmacogenomic sensitivity (GDSC). miRNA network analysis identified miR-34a as a master post-transcriptional regulator targeting BCL2, CDK4, and MYCN simultaneously. The original HDOCK docking and 100-ns MD analyses (one trajectory per complex) supported predicted binding stability for BCL2/Venetoclax (HDOCK score: -271.19), ALK/Ceritinib (-222.91), and CDK4/Abemaciclib (-219.76). The revision-stage sensitivity analysis showed that hub-hub connectivity is strongly threshold-dependent (508, 138, and 48 interactions among the exported hub nodes at confidence ≥ 0.400, 0.700, and 0.900), and that the centrality of the three priority genes is sensitive to network stringency; they are therefore described as computationally prioritized candidates rather than threshold-robust hubs. The independent Vina validation recovered the native binding sites of all five targets (top-pose centroid offsets 0.15-2.6 Å) with favorable scores for every drug-target pair (-12.3 to -6.4 kcal/mol), while pose-level RMSD values (4.8-7.3 Å) showed that rigid-receptor docking does not resolve exact ligand orientations for these flexible inhibitors; docking scores are therefore interpreted as site-level binding-competence evidence only.

CONCLUSIONS:

This study presents an integrative computational pipeline for network-based drug-target prioritization in neuroblastoma, combining multi-criteria network topology, multi-database biological validation, HDOCK docking with single-trajectory MD stability assessment, and two independent revision-stage verification analyses (AutoDock Vina re-docking and confidence-threshold sensitivity). Within the explicitly reported boundaries of these analyses, BCL2, ALK, and CDK4, together with the AURKA and beta-tubulin axes of Alisertib and Docetaxel, emerge as computationally prioritized candidates for preclinical investigation, with replicate MD simulations on high-performance computing resources and experimental target engagement identified as the required next steps.

2027-02-01·COMPUTATIONAL BIOLOGY AND CHEMISTRY

A Network-Guided Modular Framework for drug response prediction in acute myeloid leukemia

Article

作者: Wang, Yuan ; Zhao, Wenjiao ; Wu, Yurun ; Gao, Jie

Drug response prediction in acute myeloid leukemia (AML) is challenged by sample heterogeneity and high-dimensional RNA sequencing profiles. We develop NGM-AML, a modular model predicting ex vivo drug response from BeatAML2 RNA-seq and sensitivity data. After filtering, 306 Waves 1+2 samples (28055 records) serve as training and 173 Waves 3+4 samples (16123 records) as the test set across 111 drugs. Drug targets and AML prior genes are mapped to a PPI network; random walk with restart and community detection construct 45 modules. Per drug, module scores are partitioned into sensitivity and resistance components by their association with the area under the dose-response curve. The results show that NGM-AML achieves mean Pearson and Spearman correlations of 0.324 and 0.326 across drugs, with an MAE of 37.396. Pooling all test records yields a Pearson correlation of 0.703 between predicted and observed AUC. For representative drugs, Pearson correlations reach 0.780 for Venetoclax and 0.631 for Trametinib. Within patients, median Spearman correlation and NDCG@5 are 0.75 and 0.96 for drug ranking. Runtime decreases from 87125.4 s for the raw RNA-seq model to 1102.5 s for NGM-AML. Enriched processes include extracellular matrix adhesion, integrin signaling, and RTK/MAPK pathways, consistent with known AML survival and drug-resistance mechanisms.

2027-01-01·CLINICA CHIMICA ACTA

BCL-2 in leukemia: Enhancing clinical utility

Review

作者: Khan, Abida ; Khalid, Mohammad ; Bakht, Md Afroz ; Rehman, Zia Ur ; Singla, Neelam ; Ali, Md Imtiaz ; Kamal, Mohammad Azhar ; Imran, Mohd

B-cell lymphoma 2 (BCL-2) is an important anti-apoptotic protein in the mitochondrial cell death pathway and is biologically significant for leukemic cell survival, apoptosis resistance, drug resistance, and disease persistence. BCL-2 is clinically relevant in hematopathology and laboratory medicine, as it is a central regulator of apoptosis in several leukemia subtypes. This review evaluates BCL-2 primarily as a prognostic, treatment-stratifying, and venetoclax-related predictive biomarker in leukemia, while critically examining its more limited and context-dependent diagnostic contribution. We summarize existing data on the association of BCL-2 expression and functional dependency with leukemia biology, cytogenetic and molecular risk factors and survival. We also explore its use in distinguishing leukemic populations from non-malignant hematopoietic populations, primarily in conjunction with morphology, immunophenotyping, cytogenetics, molecular testing, and other markers of apoptosis. Laboratory considerations for clinical implementation are addressed, such as specimen selection, inter-platform variability, antibody and gating strategies, immunohistochemistry, flow cytometry, transcript-based assessment, functional apoptotic profiling, and preanalytical, analytical, and interpretative variability. We also discuss the clinical relevance of BCL-2 in venetoclax-based therapy, where dependence on BCL-2 may be more informative than expression. Overall, BCL-2 is better supported as prognostic and treatment-stratifying marker than a diagnostic marker in leukemia. To move BCL-2 assessment into routine laboratory practice, it will be necessary to establish harmonized thresholds for BCL-2 assays and to validate the analytical workflow and result in prospective studies. This review outlines the potential and current challenges of BCL-2 as an emerging biomarker in human leukemia within a laboratory medicine framework.

3,098

项与维奈克拉相关的新闻（医药）

2026-10-26

·BioSpace

InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization

BEIJING, Oct. 26, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced its third quarter 2026 results and business highlights for the nine-months ended September 30, 2026. In the first three quarters of 2026, driven by strong commercial execution and global business development collaborations, the Company’s revenue grew 88.2% year-on-year (YoY) to RMB 2.1 billion, and net profit reached RMB 648.3 million, as the Company sustained profitability. The Company also continued to accelerate its globalization, entering into a strategic collaboration with Eli Lilly that reflects global recognition of its innovation capabilities. The company has been continuously accelerating its pipeline development, with 14 registrational clinical trials ongoing and five new molecules entering the clinic this year. InnoCare further advanced its strategy of innovation, commercialization and globalization, building stronger momentum for long-term growth. Financial Highlights Revenue grew by 88.2% YoY to RMB 2.1 billion in the first three quarters of 2026, driven mainly by robust commercial growth and global business development collaborations. Drug sales increased by 41.5% YoY to RMB 1.4 billion for the 9 months ended September 30, 2026, driven by robust growth of orelabrutinib and contributions from the newly launched tafasitamab and zurletrectinib. Profit reached RMB 648.3 million, compared with a loss of RMB 72.0 million in the same period, mainly due to continued commercial growth and global BD collaborations. Research and Development Investment increased by 16.1% YoY to RMB 785.1 million for the 9 months ended September 30, 2026, reflecting the advancement of additional Phase III clinical trials, as well as increased investment in new technology platforms. Accelerating Globalization In the third quarter of 2026, InnoCare continued to accelerate its globalization by entering into a strategic research collaboration and license agreement with Eli Lilly. Leveraging its drug discovery platform and extensive research experience, the Company will discover and advance up to five innovative target programs, with a total deal value of up to US$ 3.35 billion. The collaboration underscores global recognition of the Company's R&D capabilities and the international competitiveness of its drug discovery platform. Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, “In the first three quarters of 2026, we sustained profitability, maintained robust commercial growth, and accelerated globalization. Our collaboration with Zenas continued to advance with increasing value realization, and we entered into a strategic collaboration with Eli Lilly, fully demonstrating our capabilities in global collaboration. Meanwhile, projects across our oncology and autoimmune pipelines progressed rapidly in China and globally, in line with our commitment to benefit patients worldwide.” Robust Commercial Growth Leveraging a diversified and highly competitive product portfolio and strong commercial execution, the Company's drug sales maintained rapid growth in the first three quarters of 2026, increasing by 41.5% YoY to RMB 1.4 billion. In 2026, all four approved indications of orelabrutinib were included in the updated National Reimbursement Drug List (NRDL). Orelabrutinib sales grew rapidly following the NRDL inclusion of the first line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) indication, while orelabrutinib maintained its exclusive indication advantage in marginal zone lymphoma (MZL). Additionally, both tafasitamab and zurletrectinib have been approved for marketing and have begun to contribute to sales. Tafasitamab is the first CD19 antibody approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in China, and the next-generation TRK inhibitor, zurletrectinib, has been prescribed in hospitals across China. Accelerating Innovation Enhancing Competitive Advantage in Hemato-Oncology As the first BCL2 inhibitor granted Breakthrough Therapy Designation (BTD) in China, mesutoclax (ICP-248) is advancing five registrational clinical trials. The latest data from the program will be presented at the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans from December 12-15, 2026. 1) The registrational Phase III trial of mesutoclax with orelabrutinib in 1L CLL/SLL has completed patient enrollment. 2) The registrational Phase II clinical trial of mesutoclax in BTK inhibitor-treated mantle cell lymphoma (MCL) has completed patient enrollment and received BTD. It is the first BCL2 inhibitor to receive BTD recognition in China. 3) The registrational Phase III clinical trial of mesutoclax in combination with orelabrutinib in r/r MCL is ongoing in China. 4) The head-to-head registrational Phase III trial of mesutoclax with azacitidine versus venetoclax with azacitidine in treatment naïve (TN) acute myeloid leukemia (AML) was initiated in China. 5) The Phase III clinical trial of mesutoclax in combination with orelabrutinib for the treatment of patients with marginal zone lymphoma (MZL) who have received at least one prior therapy has been initiated, and the combination has been granted BTD in China. In addition, global clinical development of mesutoclax in AML and myelodysplastic syndrome (MDS) is accelerating in China, the U.S., and Australia. The latest data will be presented at the 68th American Society of Hematology (ASH) Annual Meeting in 2026. Accelerating Autoimmune Pipeline, Building Second Growth Curve Orelabrutinib The NDA submission for orelabrutinib in Immune thrombocytopenia（ITP） has been accepted in China, marking orelabrutinib’s first NDA acceptance in an autoimmune indication and a significant milestone in its expansion beyond hematologic malignancies into autoimmune diseases. The Phase III clinical data will be presented at the 68th ASH Annual Meeting in 2026. The registrational Phase III clinical trial of orelabrutinib in systemic lupus erythematosus (SLE) has been accelerating patient enrollment. Orelabrutinib is the first BTK inhibitor to demonstrate significant efficacy in a Phase IIb clinical trial in SLE. Two global registrational Phase III clinical trials of orelabrutinib in primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS) are ongoing in collaboration with Zenas. Multiple studies were presented at the 10th Joint ACTRIMS-ECTRIMS Meeting in 2026, fully demonstrating the significant clinical potential of orelabrutinib in SPMS and PPMS. Two Differentiated Oral TYK2 Inhibitors Soficitinib (ICP-332) and fadeucravacitinib (ICP-488) have delivered multiple pivotal Phase II/III clinical readouts that met primary endpoints. Soficitinib 1) The Phase III clinical trial of soficitinib in patients with moderate to severe atopic dermatitis (AD) met primary endpoints. 2) The Phase II portion of the Phase II/III trial in non-segmental vitiligo has met its primary endpoint. The Company will accelerate Phase III clinical trials. 3) The global Phase II clinical trial for prurigo nodularis (PN) has continued patient enrollment in China, U.S. and Europe. 4) The Phase II/III clinical trial for moderate‑to‑severe chronic spontaneous urticaria (CSU) has completed patient enrollment. 5) The Phase II clinical trial for moderate‑to‑severe plaque psoriasis has completed patient enrollment. 6) The Phase II clinical trial in adolescent patients with moderate-to-severe AD has completed patient enrollment. Fadeucravacitinib 1) The Phase III clinical trial in patients with moderate-to-severe plaque psoriasis achieved primary endpoints. 2) The Phase II clinical trial in cutaneous lupus erythematosus (CLE) is being expedited. 3) The Phase II clinical trial in patients with Sjögren’s syndrome (SS) is ongoing. Other Autoimmune Pipelines ICP-054, a novel oral IL-17AA/AF inhibitor, has successfully enrolled healthy volunteers. The single-ascending-dose (SAD) and multiple-ascending-dose (MAD) portions are being conducted in collaboration with Zenas, with Phase I study completion expected by the end of 2026. ICP-538, the first VAV1 degrader approved to enter clinical trials in China and the second globally, has successfully enrolled patients, with the Phase I clinical study expected to complete by the end of the year. ICP-538 is a novel, potent, highly selective, orally administered molecular glue degrader targeting VAV1, a key signaling protein downstream of the T-cell and B-cell receptors. ICP-538 is being developed for the treatment of hard-to-treat autoimmune diseases, such as inflammatory bowel disease (IBD), SLE, and MS. ICP-B161, a novel bispecific antibody targeting TL1A and IL-23p19 , has been approved for clinical trials for the treatment of autoimmune diseases, including IBD. In preclinical studies, ICP-B161 demonstrated good efficacy, including significant inhibition of colitis-related symptoms. Accelerating Solid Tumor Pipeline Development Zurletrectinib, the next-generation TRK inhibitor, was granted priority review for the treatment of pediatric patients (ages 2–12) with solid tumors harboring NTRK fusions, and the NDA application has been accepted. The Company's highly differentiated ADC technology platform leverages unique linker-potent payload (LP) technology. Built on this platform, the Company will continue to develop multiple ADC drug candidates with highly differentiated efficacy and safety pro bringing a new generation of treatment options to patients with cancer. To date, three innovative ADC candidates have entered clinical development, including the Company’s first bispecific ADC. 1) ICP-B794, a novel B7-H3 targeted ADC, has accelerated Phase I dose-escalation trial, offering a promising treatment for solid tumors such as lung cancer, esophageal cancer, nasopharyngeal cancer, head and neck squamous cell carcinomas, prostate cancer, and others. 2) ICP-B208, a novel CDH17-targeted ADC, has entered clinical development, with patient enrollment underway. ICP-B208 is being developed for the treatment of gastrointestinal cancers, including gastric, colorectal, pancreatic ductal adenocarcinoma, and cholangiocarcinoma. 3) ICP-B381, a novel bi-specific ADC targeting PSMA and STEAP1, has entered clinical development in China for the treatment of solid tumors, including prostate cancer. In preclinical studies, ICP-B381 demonstrated robust and dose-dependent antitumor activities. InnoCare will accelerate the coordinated advancement of innovation, commercialization and globalization, continuing to unlock the value of its innovation globally for the benefit of patients worldwide. To know more about the detailed financial data and business updates of InnoCare 2026 Q3 results, please log in to Conference Call Information InnoCare will host a conference call at 9:00 a.m. Beijing time in Chinese on Oct. 27, 2026. Participants must register in advance of the conference call through the below link: . InnoCare Forward-looking Statements This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance. About InnoCare Pharma InnoCare (HKEX: 09969; SSE: 688428) is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing innovative drugs for the treatment of cancers and autoimmune diseases, two therapeutic areas with unmet medical needs worldwide. InnoCare has established comprehensive innovation platforms for drug discovery. To date, the Company has developed a robust product pipeline comprising three approved drugs (orelabrutinib, tafasitamab and zurletrectinib), more than ten innovative drug candidates in clinical development, and multiple programs in preclinical stages. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. For more information about InnoCare, please visit and follow us on LinkedIn. Contact Media Chunhua Lu 86-10-66609879 chunhua.lu@innocarepharma.com Investors 86-10-66609999 ir@innocarepharma.com

临床1期临床3期临床2期引进/卖出临床结果

2026-10-26

·BioSpace

Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant

Ten patients initially deemed unfit for intensive chemotherapy proceeded to stem cell transplant Transplant rate compares favorably with historical standard-of-care experience, adding to growing clinical evidence supporting mipletamig's potential to improve outcomes in frontline AML Aptevo expects the RAINIER dose optimization trial to conclude by year-end, with FDA interaction and initiation of a Phase 2 clinical trial anticipated in the first half of 2027 SEATTLE, WA / ACCESS Newswire / October 26, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced that ten patients with newly diagnosed acute myeloid leukemia (AML) have advanced to allogeneic stem cell transplant following treatment with mipletamig in combination with venetoclax and azacitidine. Stem cell transplant uses donor cells to replace a patient's blood-forming stem cells and can offer eligible patients the possibility of long-term remission or cure. Notably, ten of 47 (21%) evaluable frontline patients treated with mipletamig in combination with venetoclax and azacitidine (VEN+AZA) proceeded to allogeneic stem cell transplantation, a potentially curative treatment option. This includes nine patients from the ongoing Phase 1b RAINIER trial and one patient from the previously completed dose expansion trial. This finding is particularly encouraging in a patient population initially deemed unfit for intensive induction chemotherapy, where advanced age, underlying health conditions and other factors can limit treatment options. The ability of these patients to proceed to transplant provides an additional encouraging indication of mipletamig's clinical activity in combination with the current standard of care. The finding is also notable in the context of historical clinical experience with VEN+AZA alone. In the pivotal Phase 3 VIALE-A trial, three of 286 patients (0.7%) receiving VEN+AZA subsequently underwent stem cell transplantation* compared with (21%). Although cross-trial comparisons are limited by differences in patient populations, study design and follow-up, these observations add to the growing body of evidence supporting mipletamig's potential to improve treatment outcomes and help patients reach potentially curative treatment options. *Gangat N, et al. Venetoclax and hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: A Mayo Clinic series and comparison with VIALE-A study. American Journal of Hematology. 2024. "Each subset analysis helps us better understand the potential of mipletamig in frontline AML," said Dirk Huebner, M.D., Chief Medical Officer of Aptevo. "Our previously reported TP53 findings were particularly encouraging given the historically poor outcomes associated with that mutation. Now, we are seeing ten patients advance to stem cell transplant, a treatment that can offer AML patients the possibility of long-term remission or cure. These observations add another important dimension to the clinical activity we have reported and support continued evaluation of the mipletamig triplet." Reaching transplant matters and achieving a deep remission is a prerequisite for a successful transplant procedure. Remission reflects a reduction in leukemia, while transplant is an optimal outcome that can offer selected patients the possibility of prolonged remission or cure. Reaching transplant requires an adequate response to initial treatment, medical eligibility, and a suitable donor and treatment plan. Mipletamig is being evaluated with venetoclax and azacitidine in RAINIER, Aptevo's Phase 1b/2 study in newly diagnosed AML patients who are not eligible for intensive induction chemotherapy. The current stage of RAINIER is evaluating mipletamig dosing to guide the next stage of clinical testing. Aptevo expects to complete this work by year-end 2026 and discuss next steps with regulators in the first half of 2027. About Mipletamig Aptevo's wholly owned lead proprietary drug candidate, mipletamig, is being evaluated for the treatment of AML. Mipletamig is designed to redirect the patient's immune system to destroy leukemic cells and leukemic stem cells expressing CD123, which is overexpressed on leukemic stem cells and AML blasts. Mipletamig is designed to engage both leukemic cells and T cells of the immune system and bring them closely together to trigger the destruction of leukemic cells. Mipletamig is purposefully designed to reduce the likelihood and severity of cytokine release syndrome by using the CRIS-7-derived CD3 binding pathway, an approach that differentiates Aptevo from competitors. About Aptevo Aptevo Therapeutics Inc. (Nasdaq:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for the treatment of cancer. The Company's lead clinical candidate, mipletamig, is currently being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax and azacitidine. Mipletamig has received orphan drug designation for AML under the Orphan Drug Act. In the solid tumor space, Aptevo's lead assets are focused on well-established targets to progress novel immunomodulatory platform backbones that are conditionally active only in the tumor. This work includes advancing APVO451, a targeted trispecific immunotherapy candidate for solid tumors, and a strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology programs. The first radiopharmaceutical program is expected to target nectin-4, a tumor-associated antigen expressed in multiple solid tumor types. Both preclinical molecules are expected to advance into investigational new drug (IND)-enabling studies in 2027. The Company's eight pipeline candidates are created using its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms, which are designed to generate differentiated multispecific therapeutics. For more information, please visit . Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, statements regarding Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of mipletamig, including in combination with venetoclax and azacitidine; statements related to the progress of the RAINIER trial, including statements related to anticipated clinical and regulatory milestones; statements related to a growing number of patients treated with the mipletamig triplet advancing to stem cell transplant and mipletamig's role in offering AML patients the possibility of long-term remission or cure, statements related to the responses observed in patients with TP53-mutated AML and whether further study of mipletamig in combination with venetoclax and azacitidine will continue to show clinical benefit in patients with TP53-mutated AML; whether Aptevo's strategy will translate into an improved overall survival rate in acute myeloid leukemia (AML); whether the mipletamig data in combination therapy will be indicative of later stage clinical trials; whether Aptevo's strategy will translate into improved overall survival in AML, especially among patient subgroups with poor prognosis; its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platform; development and continued development of Aptevo's current and potential future molecules, including Aptevo's trispecific candidates and their future development and efficacy with respect to addressing multiple solid tumor types; whether pre-clinical studies of Aptevo's trispecific candidates will show the desired anti-tumor efficacy, mechanism of action and safety pro whether Aptevo's trispecific candidates will function with new mechanisms of action compared to our previous candidates and synergistically induce a biological response; the potential benefits, timing, scope and outcomes of the co-development collaboration with Niowave; and any statements containing the words "may," "continue to," "believes," "expects," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors are cautioned not to place undue reliance on any forward-looking statement. There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems; adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, and its subsequent reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events or circumstances. CONTACT: Miriam Weber Miller Vice President, Investor Relations & Corporate Communications Aptevo Therapeutics Email: IR@apvo.com or Millerm@apvo.com Phone: 206-859-6628 SOURCE: Aptevo Therapeutics View the original press release on ACCESS Newswire

免疫疗法临床3期细胞疗法孤儿药临床结果

2026-10-26

·BioSpace

PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026

Oral presentation highlights depth of responses in heavily pretreated patients with R/R HR-MDS, including two MRD-negative complete responses enabling stem cell transplantation LYT-200 demonstrated a favorable safety pro 101 patients with R/R HR-MDS and AML, with no dose-limiting toxicities or LYT-200-related serious adverse events PureTech Founded Entity, Gallop Oncology, plans to advance LYT-200 into Phase 2 STRIDE-MDS trial in patients with R/R HR-MDS following successful FDA End-of-Phase 1 meeting and receipt of Fast Track designation BOSTON--(BUSINESS WIRE)-- PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that results from the Phase 1b clinical trial of LYT-200 were presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. LYT-200 is a first-in-class monoclonal antibody targeting galectin-9, an important oncogenic driver and potent immunosuppressor. It is being advanced by PureTech's Founded Entity, Gallop Oncology (Gallop). The completed Phase 1b trial (NCT05829226) was conducted across nine U.S. sites and evaluated LYT-200 both as a monotherapy and in combination regimens across 101 heavily pretreated patients with relapsed/refractory (R/R) high-risk myelodysplastic syndromes (HR-MDS) or acute myeloid leukemia (AML). The trial included dose escalation of LYT-200 monotherapy, followed by dose escalation of LYT-200 in combination with a hypomethylating agent (HMA; azacitidine or decitabine) in patients with R/R HR-MDS and with venetoclax (VEN) and an HMA in R/R AML. As previously disclosed , topline results showed encouraging clinical activity and favorable safety in a heavily pretreated patient population. The oral presentation at ESMO provided further detail on the depth of responses observed. In R/R HR-MDS, LYT-200 at 12 mg/kg in combination with an HMA demonstrated a 36.4% complete response + partial response rate and a 45.5% overall response rate in 11 efficacy-evaluable 1 patients, all of whom had previously received HMA therapy. Notably, two patients in this treatment cohort achieved MRD-negative complete responses and subsequently proceeded to stem cell transplantation. Efficacy-evaluable R/R HR-MDS patients had a median of 3 prior lines of therapy (range: 1-5), and all (100%) had previously been treated with an HMA. Importantly, clinical responses were observed across patients with a range of mutations (i.e., BCOR, DNMT3A, SF3B1, TET2, PTPN11, KRAS, and RUNX1-RUNX1T1), and all patients had high-risk cytogenetics, which – coupled with prior exposure to treatment – suggests biologically aggressive, treatment-refractory disease with elevated risk of progression and poor clinical outcomes. Taken together, these attributes underscore the potential mutation-agnostic mechanism of LYT-200 and its potential for broad clinical use. LYT-200 demonstrated a favorable and consistent safety pro all cohorts and dose levels studied (N=101), with no dose-limiting toxicities, infusion-related reactions, LYT-200 dose reductions, or LYT-200-related serious adverse events (AEs), discontinuations, or deaths. Importantly, no overlapping or additive toxicities were observed when LYT-200 was combined with an HMA or venetoclax/HMA. “What is particularly encouraging about these findings is the combination of clinical activity, depth of response and tolerability observed in patients who have already received multiple lines of treatment,” said Guenther Koehne, MD, PhD, Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology at Baptist Health Herbert Wertheim Cancer Institute, who presented the Phase 1b results at ESMO. “In high-risk MDS, we need therapies that can achieve meaningful disease control without adding substantial treatment burden. These results provide an encouraging foundation for evaluating LYT-200 in a larger, randomized study and better understanding its potential role in treating this challenging disease.” Following a successful End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) and receipt of Fast Track designation for R/R HR-MDS , Gallop plans to advance LYT-200 into Phase 2 development. The S tudy of T wo R egimens I nvestigating D ose and E fficacy of LYT‑200 in Relapsed/Refractory High-Risk MDS ( STRIDE-MDS ) will be a randomized, double-blind, placebo-controlled Phase 2 trial enrolling approximately 125 patients with R/R HR-MDS. Patients will be randomized 2:2:1 to receive LYT-200 at 12 mg/kg plus an HMA, LYT-200 at 7.5 mg/kg plus an HMA, or placebo plus an HMA, respectively. The trial will assess the efficacy of LYT-200 as measured by the rate of complete and partial responses to support dose selection. Gallop plans to initiate the trial after securing external capital. About Myelodysplastic Syndromes Myelodysplastic syndromes (MDS) are a group of serious blood cancers characterized by ineffective blood cell production in the bone marrow, leading to anemia, infections, and bleeding complications. 2,3 MDS affects approximately 60,000-170,000 people in the United States, with an estimated 30-40% of patients diagnosed with the more aggressive form of the disease known as high-risk (HR) MDS. 2, 4 HR-MDS is associated with poor outcomes, with median survival typically less than two years following diagnosis. The current standard frontline treatments for HR-MDS are hypomethylating agents (HMAs), such as azacitidine and decitabine; however, most patients do not respond to these therapies or eventually stop benefiting from them. 5 Once the disease becomes relapsed or refractory (R/R), outcomes are especially poor, with survival often limited to only a few months. 5,6 Treatment options for patients with R/R HR-MDS remain very limited. Only one therapy has been approved by the U.S. Food and Drug Administration specifically for R/R HR-MDS in the past two decades, and it targets a genetic mutation found in only approximately 3% of patients. 5 As a result, there remains a significant unmet need for treatments for the overwhelming majority of patients with R/R HR-MDS. About LYT-200 LYT-200 is a Phase 2-ready, fully human monoclonal antibody in development for the treatment of relapsed/refractory (R/R) high-risk myelodysplastic syndromes (HR-MDS). It is the most advanced therapeutic candidate targeting galectin-9, which is an important oncogenic driver and potent immunosuppressor that plays a central role in some of the most difficult-to-treat cancers. With its mutation-agnostic, dual mechanism of action, LYT-200 is designed to address both the malignant cells and the immunosuppressive environment that sustain disease. LYT-200 has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of R/R HR-MDS in combination with a hypomethylating agent. LYT-200 has also been granted Fast Track designation from the U.S. FDA for the treatment of acute myeloid leukemia (AML). About Gallop Oncology Gallop Oncology is a clinical-stage biotechnology company dedicated to transforming the treatment paradigm for hematological malignancies. Its lead candidate, LYT-200, is a first-in-class, mutation-agnostic antibody in development for the treatment of relapsed/refractory (R/R) high-risk myelodysplastic syndromes (HR-MDS). Gallop Oncology was founded by and is currently wholly owned by PureTech Health plc (LSE: PRTC). For more information, please visit . About PureTech Health PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders. For more information, visit or connect with us on X (formerly Twitter) @puretechh. _______________________________ 1 Efficacy evaluable is defined in the protocol as all patients who received a minimum one full cycle of LYT-200 (four doses) and had a minimum of one post-baseline disease assessment. The intent-to-treat population for the R/R HR-MDS cohort was n=12. 2 American Cancer Society. (2023). What Is Myelodysplastic Syndrome? Retrieved from 3 National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes (Version 2.2024). Retrieved from 4 Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., & Haase, D. (2012). Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood, 120 (12), 2454-2465. 5 Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., et al. (2016). Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): A randomised, controlled, phase 3 trial. Lancet Oncology, 17 (4), 496-508. (16)00009-7 6 Prébet, T., Gore, S. D., Esterni, B., Gardin, C., Itzykson, R., Thepot, S., Quesnel, B., Dreyfus, F., Beyne-Rauzy, O., Vey, N., Recher, C., Adès, L., Fenaux, P., & Groupe Francophone des Myélodysplasies. (2011). Outcome of patients with higher-risk myelodysplastic syndromes after azacitidine treatment failure. Journal of Clinical Oncology, 29 (24), 3322-3327. Contacts PureTech Public Relations publicrelations@puretechhealth.com Investor Relations IR@puretechhealth.com

临床1期临床结果快速通道临床2期临床3期

100 项与维奈克拉相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10679	维奈克拉	L01XX52	DB11581

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
复发性套细胞淋巴瘤	日本	AbbVie GK	2025-03-27
难治性套细胞淋巴瘤	日本	AbbVie GK	2025-03-27
难治性慢性淋巴细胞白血病	日本	AbbVie GK	2019-09-20
复发性慢性淋巴细胞白血病	日本	AbbVie GK	2019-09-20
小淋巴细胞淋巴瘤	美国	AbbVie, Inc.	2018-06-08
成人急性髓性白血病	欧盟	AbbVie Deutschland GmbH & Co. KG	2016-12-04
成人急性髓性白血病	冰岛	AbbVie Deutschland GmbH & Co. KG	2016-12-04
成人急性髓性白血病	列支敦士登	AbbVie Deutschland GmbH & Co. KG	2016-12-04
成人急性髓性白血病	挪威	AbbVie Deutschland GmbH & Co. KG	2016-12-04
急性髓性白血病	加拿大	AbbVie AS	2016-10-31
慢性淋巴细胞白血病	美国	AbbVie, Inc.	2016-04-11

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤溶解综合征	临床3期	美国	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	澳大利亚	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	法国	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	希腊	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	塞尔维亚	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	西班牙	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	中国台湾	AbbVie, Inc.	2024-08-05
肿瘤溶解综合征	临床3期	英国	AbbVie, Inc.	2024-08-05
复发性急性髓细胞白血病	临床3期	美国	AbbVie, Inc.	2022-10-01
复发性急性髓细胞白血病	临床3期	美国	Genentech, Inc.	2022-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05105841 (CTgov)	临床2期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤	20	Venetoclax+Obinutuzumab (Venetoclax + Obinutuzumab)	積簾遞選願構網糧遞衊 = 醖獵夢願構鏇繭遞遞遞淵壓繭窪膚選憲遞顧憲 (淵廠鏇鹹簾顧獵襯觸鹹, 積獵願網鏇窪願築網顧 ~ 鹽蓋遞醖顧範鹽築襯顧) 更多	-	2026-10-21
				Ibrutinib+Venetoclax (Venetoclax + Ibrutinib)	積簾遞選願構網糧遞衊 = 襯餘範夢蓋齋糧鑰醖構淵壓繭窪膚選憲遞顧憲 (淵廠鏇鹹簾顧獵襯觸鹹, 顧顧網鏇簾齋範憲憲築 ~ 簾觸鹹願範鏇觸鑰築鬱) 更多
NCT03609593 (CTgov)	临床2期	慢性淋巴细胞白血病	42	Bendamustine+Venetoclax+Rituximab	鹽壓積衊夢築窪築襯願 = 糧範製淵願蓋膚簾鬱鹹糧簾鹹壓憲廠選壓壓顧 (築範積構遞憲齋鹽衊壓, 衊範襯積鏇鹹製廠鏇蓋 ~ 獵淵鑰鬱膚蓋網鹹範築) 更多	-	2026-10-07
NCT04817241 (CTgov)	临床1/2期	急性髓性白血病	5	Bone Marrow Aspiration and Biopsy+Decitabine and Cedazuridine+Venetoclax (Phase Ib (Decitabine and Cedazuridine, Venetoclax))	窪製齋觸構窪醖築夢壓 = 艱積簾餘鹹窪繭膚鏇廠鹹遞鏇鏇構築遞構鏇積 (積網簾壓鹹鹹襯壓壓夢, 齋積憲齋膚衊選觸獵壓 ~ 顧艱襯願蓋艱築襯鹹廠) 更多	-	2026-10-06
				Bone Marrow Aspiration and Biopsy+Decitabine and Cedazuridine+Venetoclax (Arm I (Decitabine and Cedazuridine, Venetoclax))	鏇壓淵構齋壓蓋夢構艱(鹹選廠獵壓膚製夢構製) = 膚醖觸鹽觸蓋選鹽膚夢淵製繭觸鑰顧窪觸顧願 (觸夢構積鏇醖蓋觸構範, 觸鹹窪顧遞鹽淵壓構鹹 ~ 網鑰衊鹹鑰鬱構壓蓋餘) 更多
NCT05853965 (BELI(E)VE, Pubmed \| BMC Cancer)	临床1/2期	t(11;14)	33	Belantamab mafodotin+Venetoclax+Dexamethasone	觸範獵襯醖簾顧鹹構遞(願鬱淵顧壓壓獵淵夢艱) = The most common ocular AEs were blurred vision (59%) and dry eye (47%). The majority of ocular AEs were grade 1-2. The most common non-ocular AEs were infusion-related reactions (62%) and musculoskeletal pain (41%). 衊顧襯夢鹽窪鹽憲夢鹹 (餘衊鏇獵願選齋艱選願 )	积极	2026-09-16
				Belantamab mafodotin+Venetoclax
NCT05947851 (BELLWAVE-010, CSCO2026)	临床3期	慢性淋巴细胞白血病 \| 淋巴细胞白血病	31	Nemtabrutinib 45 mg + Venetoclax	遞顧齋淵獵製鹹衊餘網(鏇艱壓製積願繭選艱鏇) = 憲窪構鑰衊憲齋餘窪蓋選鹹艱糧願獵廠築獵鹽 (觸範蓋壓鬱餘餘醖鏇築 ) 更多	积极	2026-09-11
				Nemtabrutinib 65 mg + Venetoclax	遞顧齋淵獵製鹹衊餘網(鏇艱壓製積願繭選艱鏇) = 蓋醖鹹積鹽窪觸觸網餘選鹹艱糧願獵廠築獵鹽 (觸範蓋壓鬱餘餘醖鏇築 ) 更多
CSCO2026	N/A	急性髓性白血病	70	CACAG-VEN方案	鬱製糧簾憲鑰夢醖鏇範(繭壓夢獵網築蓋襯製獵) = 在非血液学毒性方面,两组最常见的3-4 级不良事件主要是中性粒细胞减少伴发热和肺部感染。在第1 个疗程中,1 例因脓毒血症死亡患者为“3+7”组,CACAG-VEN 组无严重不良事件。糧選膚醖網簾憲糧艱衊 (繭積構膚憲窪製願齋廠 ) 更多	积极	2026-09-11
				3+7方案
NCT04801797 (PARADIGM, Pubmed \| N Engl J Med)	临床2期	急性髓性白血病	172	Azacitidine plus Venetoclax	鹽鬱獵網範醖艱鑰繭製(築選醖遞齋顧繭範襯獵) = 鹹憲醖窪艱積簾鹽網衊壓鏇憲構簾鹽範餘築鬱 (齋觸廠鑰選網簾網鹹鬱, 19 ~ 39) 更多	积极	2026-09-03
				Induction Chemotherapy	鹽鬱獵網範醖艱鑰繭製(築選醖遞齋顧繭範襯獵) = 廠築積繭壓淵願積憲築壓鏇憲構簾鹽範餘築鬱 (齋觸廠鑰選網簾網鹹鬱, 30 ~ 52) 更多
NCT03984448 (ALLIANCE A051701, Pubmed \| Lancet Haematol)	临床2/3期	高级别B细胞淋巴瘤伴 MYC 和 BCL2 和/或 BCL6 重排	73	DA-EPOCH-R plus Venetoclax	憲膚衊製築艱襯積鹽鹽(醖顧獵夢夢顧齋齋積繭) = The most common grade 3-4 non-haematological adverse event was febrile neutropenia, occurring in 15 (43%) of 35 patients in the DA-EPOCH-R plus venetoclax group and 11 (37%) of 30 patients in the DA-EPOCH-R group. 繭願遞鑰構膚網鹹簾獵 (網簾襯齋積積製製襯製 )	不佳	2026-09-01
				DA-EPOCH-R
NCT04965493 (BRUIN CLL-322, Pubmed \| Lancet)	临床3期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤	639	Pirtobrutinib plus Venetoclax-Rituximab	淵衊鬱衊鹹繭遞範衊廠(齋鏇壓願簾衊廠衊廠窪) = 鑰願襯選鹹鑰壓襯簾衊繭襯餘觸窪壓衊膚鏇鹹 (獵鏇壓壓襯夢憲鹹淵構, 31.7 ~ not estimable) 更多	积极	2026-08-01
				Venetoclax-Rituximab	簾製廠糧獵構鹹蓋築蓋(選衊廠醖範餘蓋齋簾壓) = 糧鹹膚鬱窪壓廠選衊餘鹹願醖範築糧鏇膚鏇鹽 (繭餘蓋鹹壓製範積簾憲, 65.7 ~ 77.0) 更多
NCT03613532 (Pubmed \| Transplant Cell Ther)	临床1期	急性髓性白血病 TP53 mutations	23	Venetoclax+FluBu2+Post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil	餘憲蓋觸遞積醖願壓範(蓋獵糧獵選鏇鑰選網夢) = 膚壓憲獵獵廠鹹簾獵醖遞鑰顧鏇膚遞積獵鬱憲 (醖簾繭獵醖襯衊餘鏇簾, 41.7 ~ 83.7) 更多	积极	2026-08-01